Elicio Therapeutics (ELTX) Other Operating Expenses (2020 - 2024)

Elicio Therapeutics' (ELTX) quarterly Other Operating Expenses came in at $3000.0 in Q1 2024, down 97.14% on a QoQ basis from $105000.0 in Q4 2023.

Elicio Therapeutics (ELTX) Other Operating Expenses (2020 - 2024) Analysis & Trends

Elicio Therapeutics (ELTX) has 4 years of Other Operating Expenses data on file, last reported at $3000.0 in Q1 2024.

Quarterly Other Operating Expenses changed N/A year-over-year to $3000.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $3000.0 (changed N/A YoY) and the FY2024 annual result came in at $3000.0, changed N/A from the prior year.
Other Operating Expenses eased to $3000.0 in Q1 2024, from $105000.0 in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $105000.0 in Q4 2023 to a low of -$7.5 million in Q1 2021.
A 4-year average of -$2.4 million and a median of -$1.2 million in 2020 frame the typical range for Other Operating Expenses.
The widest YoY moves for Other Operating Expenses: up 1545.15% in 2021, down 1545.15% in 2021.
Tracing ELTX's Other Operating Expenses over 4 years: stood at -$5.6 million in 2020, then slumped by 32.38% to -$7.5 million in 2021, then soared by 101.41% to $105000.0 in 2023, then sank by 97.14% to $3000.0 in 2024.
The last three Other Operating Expenses figures came in at $3000.0 (Q1 2024), $105000.0 (Q4 2023), and -$105000.0 (Q3 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Elicio Therapeutics	58.41 Mn	34.91 Mn	-

Download Data